TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3571097
Drug: Liquid carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid carbohydrate (LCHO) 45 g
Study: 3571097
Drug: Solid carbohydrate
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid carbohydrate confectionery bar (SCHO) 45 g
Study: 3571097
Drug: High-CHO meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-CHO meal (200 g) + Solid carbohydrate confectionery bar (M + SCHO)
Study: 30453477
Drug: Daily tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily tryptophan intake
Study: 30453477
Drug: Daily protein
Normalized name: Supra Clens Daily Protein Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily protein intake
Study: 30453477
Drug: Daily energy
Normalized name: CVS Daily Energy Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily energy intake
Study: 30453477
Drug: Serum insulin-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum insulin-like growth factor-1 (IGF-1)
Study: 20653695
Drug: nebicapone 150
Normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebicapone 150 mg
Study: 20653695
Drug: entacapone 200
Normalized name: entacapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: entacapone 200 mg (active control)
Study: 20653695
Drug: nebicapone 50
Normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebicapone 50 mg
Study: 20653695
Drug: nebicapone 100
Normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebicapone 100 mg
Study: 11151264
Drug: Topical nonpreserved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nonpreserved steroids for 2 weeks followed by punctal occlusion
Study: 8656364
Drug: Pressure patching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure patching after application of antibiotic/steroid ointment (A/S)
Study: 8656364
Drug: A/S ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/S ointment twice a day without patching
Study: 1290331
Drug: Lo-Estrin (norethindrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lo-Estrin (norethindrone acetate 1.5 mg plus ethinyl estradiol 0.030 mg)
Study: 1290331
Drug: Lo-Femenal (norgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lo-Femenal (norgestrel 0.30 mg plus ethinyl estradiol 0.030 mg)
Study: 6721124
Drug: Flunitrazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1 mg orally the night before operation and 1 mg on the morning of operation)
Study: 6721124
Drug: Pentobarbital (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (100 mg orally the night before operation) + Atropine (0.01 mg/kg intramuscular) + Pethidine (1 mg/kg intramuscular on the morning of operation)
Study: 16675212
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate combination (SFC) 50/250 microg one inhalation twice daily (bid)
Study: 16675212
Drug: Formoterol/budesonide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol/budesonide combination (FBC) 6/200 microg two inhalations bid
Study: 15449510
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hyaluronate/2.5 ml (verum)
Study: 15449510
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg hyaluronate/2.5 ml (control)
Study: 22995543
Drug: Group PF
Normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group PF (2 mg/kg propofol+1 mcg/kg fentanyl)
Study: 22995543
Drug: Group P
Normalized name: High mobility group protein HMGI-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P (2 mg/kg propofol alone)
Study: 22995543
Drug: Group PMF
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group PMF (2 mg/kg propofol+1 mcg/kg fentanyl+0.02 mg/kg midazolam)
Study: 22995543
Drug: Group E
Normalized name: Prostaglandin group E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group E (0.2 mg/kg etomidate alone)
Study: 22995543
Drug: Group EF
Normalized name: Klor-Con/EF
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group EF (0.2 mg/kg etomidate+1 mcg/kg fentanyl)
Study: 22995543
Drug: Group EMF
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group EMF (0.2 mg/kg etomidate+1 mcg/kg fentanyl+0.02 mg/kg midazolam)
Study: 22321279
Drug: tolvaptan 15
Normalized name: tolvaptan 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolvaptan 15 - 60 mg daily
Study: 19950759
Drug: Bio-calcium from
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-calcium from shells Pinctada maxima (260 mg of elemental calcium, three times a day)
Study: 19950759
Drug: Inorganic CaCO3
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic CaCO3 (500 mg daily)
Study: 15353386
Drug: Recruitment strategy
Normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment strategy from professional sources (e.g., community agencies)
Study: 15353386
Drug: Recruitment strategy
Normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment strategy from non-professional sources (e.g., health fairs)
Study: 12136614
Drug: Antiarrhythmic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic agents (mainly amiodarone)
Study: 9534006
Drug: Oscillations of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillations of cytoplasmic Ca2+ concentration [(Ca2+]i) in beta cells; specific dosage and duration not available.
Study: 9534006
Drug: Insulin secretion;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin secretion; specific dosage and duration not available.
Study: 7698624
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg daily) and Amoxicillin (1 g twice daily) for 2 weeks (Group A)
Study: 7698624
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg daily) alone for 2 weeks (Group B)
Study: 30558758
Drug: Optimized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized medical therapy (OMT)
Study: 25880052
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg three times a day for 3 days before operation
Study: 23996340
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg/day) for 4 weeks
Study: 23996340
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg/day) for 8 weeks
Study: 17445902
Drug: Bromfenac ophthalmic
Normalized name: bromfenac ophthalmic
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac ophthalmic solution 0.09% (Xibrom)
Study: 11254817
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (budesonide, beclomethasone dipropionate)
Study: 11254817
Drug: Non-corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-corticosteroid treatment (reference group)
Study: 9881085
Drug: D10 Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: D10 Group (10 mg dexamethasone)
Study: 9881085
Drug: D20 Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: D20 Group (20 mg dexamethasone)
Study: 9881085
Drug: D2 Group
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 Group (not specified dexamethasone dosage)
Study: 28960244
Drug: Case-only approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case-only approach for measuring markers predicting treatment effects
Study: 29441973
Drug: Compound clotrimazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compound clotrimazole cream (control)
Study: 19520901
Drug: Shame transformation
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shame transformation treatment program
Study: 11115460
Drug: Isotonic glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic glucose infusion
Study: 8784112
Drug: Tirilazad mesylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate, 6 mg/kg per day for 3 days
Study: 1628130
Drug: Pentaglobin (IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaglobin (IgM and IgA enriched intravenous immunoglobulin)
Study: 6381968
Drug: Oestrogen/progestogen +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen/progestogen + Calcium (0.5 g daily)
Study: 6381968
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Calcium (0.5 g daily)
Study: 24751323
Drug: Dihydrotestosterone (DHT)
Normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone acetate (DB13951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrotestosterone (DHT) 70 mg daily transdermal treatment
Study: 8732120
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus radiation and IL‐2
Study: 26795622
Drug: 0.05 %
Normalized name: CTx4 0.05 % Oral Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 % chlorhexidine digluconate (CHX)/herbal extract combination
Study: 26795622
Drug: 0.1 %
Normalized name: carbon monoxide 0.1 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 % chlorhexidine solution
Study: 22378155
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral lisinopril 2.5 mg (n = 17)
Study: 22378155
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral placebo (n = 16)
Study: 21076717
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day folic acid supplementation
Study: 15886721
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg/day for 12 weeks
Study: 15886721
Drug: Haloperidol 20
Normalized name: haloperidol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 20 mg/day for 12 weeks
Study: 10834778
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia with morphine sulfate (PCA)
Study: 9105543
Drug: Meloxicam (7.5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (7.5-30 mg)
Study: 9105543
Drug: Meloxicam (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (various formulations)
Study: 8371127
Drug: Clarithromycin suspension
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin suspension 7.5 mg/kg bodyweight twice daily
Study: 8371127
Drug: Amoxycillin suspension
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin suspension 125 mg (bodyweight < 25 kg) or 250 mg (bodyweight ≥ 25 kg) three times a day
Study: 3524488
Drug: Papaverine 60
Normalized name: papaverine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine 60 mg added to cold cardioplegia
Study: 26282062
Drug: Maxacalcitol topical
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maxacalcitol topical ointment (22‐oxacalcitriol [OCT]), applied twice daily for 8 weeks
Study: 26282062
Drug: Maxacalcitol topical
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maxacalcitol topical ointment (22‐oxacalcitriol [OCT])
Study: 22307384
Drug: Teriflunomide 7
Normalized name: teriflunomide 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriflunomide 7 mg/day
Study: 30729028
Drug: Teriflunomide 14
Normalized name: teriflunomide 14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriflunomide 14 mg/day
Study: 22307384
Drug: Teriflunomide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriflunomide (both doses)
Study: 20609215
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion (single day or five days, eight hours)
Study: 18048820
Drug: Topical tazarotene
Normalized name: tazarotene Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tazarotene
Study: 16211753
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg orally, twice daily for 2.5 days)
Study: 7726484
Drug: Intranasal pirodavir
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal pirodavir (2 mg per treatment) six times daily for 5 days
Study: 7726484
Drug: Intranasal pirodavir
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal pirodavir
Study: 31665059
Drug: DISE-assisted titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: DISE-assisted titration
Study: 31665059
Drug: Conventional subjective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional subjective titration method
Study: 28893675
Drug: Non-opioid medication
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid medication therapy
Study: 26496285
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and Root Planing (SRP) + Low-Level Laser Therapy (LLLT)
Study: 19590518
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no injection of TA)
Study: 16328318
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (5 mg, 10 mg, 20 mg, 30 mg bid)
Study: 2193560
Drug: Adenosine 3
Normalized name: adenosine 3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 3 mg
Study: 2193560
Drug: Adenosine 6
Normalized name: adenosine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 6 mg
Study: 2193560
Drug: Adenosine 9
Normalized name: adenosine 90 MG in 30 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 9 mg
Study: 2193560
Drug: Adenosine 6
Normalized name: adenosine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 6 mg followed by 12 mg if necessary
Study: 2193560
Drug: Verapamil 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 5 mg followed by 7.5 mg if necessary
Study: 6818806
Drug: 2-4 mg
Normalized name: hexylresorcinol 2.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-4 mg of micronized oestradiol-17 beta taken orally
Study: 6818806
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of oestradiol-17 beta applied cutaneously
Study: 6818806
Drug: Doubling of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling of the oral dose from 2 mg to 4 mg
Study: 28225996
Drug: Diacerein as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein as an add-on to metformin
Study: 25701295
Drug: Color-coded prefilled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Color-coded prefilled medication syringes
Study: 25701295
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medication administration methods
Study: 19717184
Drug: Otamixaban 0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban 0.035 mg/kg/h
Study: 19717184
Drug: Otamixaban 0.070
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban 0.070 mg/kg/h
Study: 19717184
Drug: Otamixaban 0.105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban 0.105 mg/kg/h
Study: 19717184
Drug: Otamixaban 0.140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban 0.140 mg/kg/h
Study: 19717184
Drug: Otamixaban 0.175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban 0.175 mg/kg/h
Study: 19717184
Drug: Control (unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (unfractionated heparin + eptifibatide)
Study: 15942583
Drug: Bivalirudin (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (bolus of 50 mg in priming solution, 1.0 mg/kg for the patient, followed by an infusion of 2.5 mg . kg(‐1) . h(‐1) until 15 minutes before the conclusion of cardiopulmonary bypass)
Study: 3556133
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intravenous and oral Pentoxifylline with walk training
Study: 12036640
Drug: Intracameral cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral cefuroxime 1 mg
Study: 12036640
Drug: Control (nonadministration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nonadministration of intracameral antibiotic prophylaxis)
Study: 24560365
Drug: Multi-drug resistance
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug resistance (MDR) identified
Study: 22366293
Drug: Insulin regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin regimen A
Study: 22366293
Drug: Insulin regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin regimen B
Study: 20369095
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (bar) - splinted mini-implants inserted using a prefabricated stainless steel guide
Study: 20369095
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (ball) - splinted mini-implants placed without a guide
Study: 18380825
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of i.v. furosemide
Study: 18380825
Drug: Oral fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluids only (control)
Study: 16280073
Drug: Menopur (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menopur (subcutaneous, SC)
Study: 16280073
Drug: Repronex (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repronex (subcutaneous, SC)
Study: 12371576
Drug: Extended Services
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended Services Intervention (ESI) - monthly phone contacts and referral information as needed.
Study: 7055527
Drug: Diazepam 20
Normalized name: diazePAM 20 mg rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 20 mg (male) / Diazepam 10 mg (female) via Z-track injection technique
Study: 7055527
Drug: Hydroxyzine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 100 mg i.m.
Study: 7055527
Drug: Diazepam via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam via Z-track injection technique
Study: 7055527
Drug: Diazepam via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam via other injection techniques (not specified)
Study: 25153538
Drug: Alectinib (300-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib (300-900 mg twice a day)
Study: 25153538
Drug: Alectinib (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib (300-600 mg twice a day)
Study: 25153538
Drug: Alectinib (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib (900 mg twice a day)
Study: 25153538
Drug: Alectinib (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib (not specified dose)
Study: 20933178
Drug: Atomoxetine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (1.2 mg/kg per day, reached at 3 weeks)
Study: 15866769
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for elevated blood lead concentrations (20-44 microg/dL)
Study: 9728588
Drug: Gemcitabine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine with concurrent radiation therapy
Study: 9728588
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and vinblastine as induction chemotherapy
Study: 23596815
Drug: Periplaneta americana
Normalized name: PERIPLANETA AMERICANA
DrugBank: Periplaneta americana (DB10417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periplaneta americana extract plus conventional medication for sepsis
Study: 21312348
Drug: Multidisciplinary team
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidisciplinary team care program (12 weeks, 1 day per week; individual treatments, group exercises, and group education)
Study: 30574797
Drug: HTX-019 130
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-019 130 mg via 2-min injection (9 ml/min)
Study: 30574797
Drug: HTX-019 130
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-019 130 mg via 30-min infusion (296 ml/h)
Study: 30574797
Drug: HTX-019 130
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-019 130 mg via injection
Study: 30574797
Drug: HTX-019 130
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-019 130 mg via infusion
Study: 24888810
Drug: Figitumumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figitumumab (20 mg/kg) plus paclitaxel (200 mg/m(2)) and carboplatin (AUC 6 mg · min/mL)
Study: 23082142
Drug: GnRH agonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonists and GnRH antagonists
Study: 19923505
Drug: Morphine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine IV 20 microg x kg(‐1) x h(‐1)
Study: 19923505
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% 0.1 mL x kg(‐1) x h(‐1) via FIC catheter
Study: 10215751
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of recombinant human growth hormone (rhGH) at a dose of 0.6 IU
Study: 10215751
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of recombinant human growth hormone (rhGH) at a dose of 1.2 IU
Study: 10215751
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of recombinant human growth hormone (rhGH) at a dose of 1.8 IU